Amy L. Sherborne

3.0k total citations
25 papers, 785 citations indexed

About

Amy L. Sherborne is a scholar working on Molecular Biology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Amy L. Sherborne has authored 25 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 9 papers in Hematology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Amy L. Sherborne's work include Multiple Myeloma Research and Treatments (8 papers), DNA Repair Mechanisms (6 papers) and Protein Degradation and Inhibitors (5 papers). Amy L. Sherborne is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), DNA Repair Mechanisms (6 papers) and Protein Degradation and Inhibitors (5 papers). Amy L. Sherborne collaborates with scholars based in United Kingdom, United States and Italy. Amy L. Sherborne's co-authors include Richard S. Houlston, Steve Paterson, Jane L. Hurst, Paula Stockley, Michael D. Thom, Daniel Chubb, Sara E. Dobbins, P. Yussanne, Robert J. Beynon and William Ollier and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Amy L. Sherborne

25 papers receiving 772 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy L. Sherborne United Kingdom 14 297 179 177 154 151 25 785
Lisa M. Davis United States 21 479 1.6× 83 0.5× 95 0.5× 139 0.9× 234 1.5× 38 1.2k
Madina Sukhanova United States 18 250 0.8× 131 0.7× 147 0.8× 201 1.3× 206 1.4× 68 823
Lars A. Forsberg Sweden 15 546 1.8× 59 0.3× 124 0.7× 120 0.8× 560 3.7× 26 1.3k
Timothy Erickson United States 17 454 1.5× 54 0.3× 20 0.1× 55 0.4× 234 1.5× 26 1.1k
Vanessa L. Horner United States 16 426 1.4× 32 0.2× 35 0.2× 15 0.1× 221 1.5× 34 852
Suzanne McElwaine United Kingdom 11 263 0.9× 48 0.3× 49 0.3× 169 1.1× 66 0.4× 14 578
Norah R. McCabe United States 12 846 2.8× 194 1.1× 188 1.1× 707 4.6× 133 0.9× 19 1.5k
Androulla Economou United Kingdom 10 1.2k 4.0× 35 0.2× 113 0.6× 24 0.2× 1.2k 8.3× 11 1.8k
Ross Kettleborough United Kingdom 10 659 2.2× 17 0.1× 49 0.3× 128 0.8× 225 1.5× 11 1.2k
Adam W. Mailloux United States 18 229 0.8× 38 0.2× 269 1.5× 247 1.6× 40 0.3× 44 979

Countries citing papers authored by Amy L. Sherborne

Since Specialization
Citations

This map shows the geographic impact of Amy L. Sherborne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy L. Sherborne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy L. Sherborne more than expected).

Fields of papers citing papers by Amy L. Sherborne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy L. Sherborne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy L. Sherborne. The network helps show where Amy L. Sherborne may publish in the future.

Co-authorship network of co-authors of Amy L. Sherborne

This figure shows the co-authorship network connecting the top 25 collaborators of Amy L. Sherborne. A scholar is included among the top collaborators of Amy L. Sherborne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy L. Sherborne. Amy L. Sherborne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kaiser, Martin, Andrew Hall, Katrina Walker, et al.. (2023). Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. Journal of Clinical Oncology. 41(23). 3945–3955. 54 indexed citations
2.
3.
Hoang, Phuc H., Alex J. Cornish, Amy L. Sherborne, et al.. (2020). An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics. Blood Cancer Journal. 10(10). 101–101. 15 indexed citations
4.
Jenner, Matthew, Amy L. Sherborne, Andrew Hall, et al.. (2019). Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172). Blood. 134(Supplement_1). 3162–3162. 1 indexed citations
5.
6.
Hall, Andrew, Katrina Walker, Amy L. Sherborne, et al.. (2018). Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone. Blood. 132(Supplement 1). 4482–4482. 8 indexed citations
7.
Ojha, Juhi, Iryna Dyagil, Stuart C. Finch, et al.. (2018). Genomic characterization of chronic lymphocytic leukemia (CLL) in radiation-exposed Chornobyl cleanup workers. Environmental Health. 17(1). 43–43. 11 indexed citations
8.
Mirabella, Fabio, David C. Johnson, Amy L. Sherborne, et al.. (2017). The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma. Blood. 130. 3072–3072. 4 indexed citations
9.
Sherborne, Amy L., Vallari Shah, Sidra Ellis, et al.. (2017). Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial. Blood. 130. 1767–1767. 2 indexed citations
10.
Sherborne, Amy L., et al.. (2017). A pooled mutational analysis identifies ionizing radiation-associated mutational signatures conserved between mouse and human malignancies. Scientific Reports. 7(1). 7645–7645. 18 indexed citations
11.
Sherborne, Amy L., Vincent Lavergne, Katharine Yu, et al.. (2016). Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors. Clinical Cancer Research. 23(7). 1852–1861. 24 indexed citations
12.
Chubb, Daniel, Peter Broderick, Sara E. Dobbins, et al.. (2016). Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nature Communications. 7(1). 11883–11883. 124 indexed citations
13.
Dobbins, Sara E., Peter Broderick, Daniel Chubb, et al.. (2016). Undefined familial colorectal cancer and the role of pleiotropism in cancer susceptibility genes. Familial Cancer. 15(4). 593–599. 9 indexed citations
14.
Sherborne, Amy L., et al.. (2015). Mutational Analysis of Ionizing Radiation Induced Neoplasms. Cell Reports. 12(11). 1915–1926. 28 indexed citations
15.
Ma, Yussanne, Sara E. Dobbins, Amy L. Sherborne, et al.. (2013). Developmental timing of mutations revealed by whole-genome sequencing of twins with acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences. 110(18). 7429–7433. 33 indexed citations
16.
Stockley, Paula, Steven A. Ramm, Amy L. Sherborne, et al.. (2013). Baculum morphology predicts reproductive success of male house mice under sexual selection. BMC Biology. 11(1). 66–66. 68 indexed citations
17.
Moutsianas, Loukas, Victor Enciso-Mora, P. Yussanne, et al.. (2011). Multiple Hodgkin lymphoma–associated loci within the HLA region at chromosome 6p21.3. Blood. 118(3). 670–674. 24 indexed citations
18.
Pastorczak, Agata, Patryk Górniak, Amy L. Sherborne, et al.. (2011). Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population. Leukemia Research. 35(11). 1534–1536. 42 indexed citations
19.
20.
Sherborne, Amy L., Michael D. Thom, Steve Paterson, et al.. (2007). The Genetic Basis of Inbreeding Avoidance in House Mice. Current Biology. 17(23). 2061–2066. 151 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisa M. Davis Breakdown of academic impact, for papers by Madina Sukhanova Breakdown of academic impact, for papers by Lars A. Forsberg Breakdown of academic impact, for papers by Timothy Erickson Breakdown of academic impact, for papers by Vanessa L. Horner Breakdown of academic impact, for papers by Suzanne McElwaine Breakdown of academic impact, for papers by Norah R. McCabe Breakdown of academic impact, for papers by Androulla Economou Breakdown of academic impact, for papers by Ross Kettleborough Breakdown of academic impact, for papers by Adam W. Mailloux
Rankless by CCL
2026